Research and Development Investment: Regeneron Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.

Biotech R&D: Regeneron vs. Viridian's Decade of Growth

__timestampRegeneron Pharmaceuticals, Inc.Viridian Therapeutics, Inc.
Wednesday, January 1, 20141271353000293000
Thursday, January 1, 201516205770001002000
Friday, January 1, 20162052295000888000
Sunday, January 1, 2017207514200019623000
Monday, January 1, 2018218610000030421000
Tuesday, January 1, 2019303660000034794000
Wednesday, January 1, 2020273500000028304000
Friday, January 1, 2021290810000056886000
Saturday, January 1, 20223592500000100894000
Sunday, January 1, 20234439000000159765000
Monday, January 1, 20245132000000
Loading chart...

Igniting the spark of knowledge

A Decade of Innovation: R&D Investments in Biotech Giants

In the ever-evolving landscape of biotechnology, research and development (R&D) investments are pivotal. Over the past decade, Regeneron Pharmaceuticals, Inc. and Viridian Therapeutics, Inc. have demonstrated contrasting trajectories in their R&D expenditures. Regeneron, a leader in the field, has consistently increased its R&D spending, culminating in a remarkable 250% growth from 2014 to 2023. This surge underscores their commitment to innovation and maintaining a competitive edge. In contrast, Viridian Therapeutics, while smaller in scale, has shown a significant upward trend, with a staggering 54,000% increase in R&D expenses over the same period. This growth reflects Viridian's strategic focus on expanding its research capabilities. As we look to the future, these investments highlight the dynamic nature of the biotech industry and the relentless pursuit of groundbreaking therapies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025